心力衰竭的放射性核素显像评价

心力衰竭的放射性核素显像评价何作祥国家心血管病中心心血管病国家重点实验室中国医学科学院阜外心血管病医院第三届全国心血管疾病检验及影像诊断学论坛,2012MyocardialPerfusionGatedSPECTWangF,etal.EurJNuclMedMolImaging,2009RegionalwallmotioninDCMbygated

SPECTandcardiacMRI(n=36)CineMRIGatedSPECTSeverehypokinesiaAkinesiaordyskinesiaTotalSeverehypokinesia5559564Akinesiaordyskinesia242448Total57933612WangF,etal.EurJNuclMedMolImaging2009;36:1611–1621Leftventricularfunction:MUGAleftlateralLAOanteriorPositron-labeledtraceranalogsforeitherfattyacidsorglucoseTaegtmeyerH,JNuclMed2010;51:80S–87SMyocardialViabilityClinical–anginaPET(goldstandard)MRIThalliumDobutamineEchoGuludecDL,EurJNuclMedMolImaging(2008)35:1709–172412MyocardialSPECTandPET/CTImagingDCBASestamibiFDGSestamibiFDGESestamibiFFDGMyocardialSPECTandPET/CTImagingFDGFDGFDGSestamibiSestamibiSestamibiMyocardialSPECTandPET/CTImagingQPSQGS

7778810131417232116141313101020SurvivalinPatientswithPET“Mismatch”04812162024283200.20.40.60.81.0

RevascularizationMedicalTherapyLowRank

2=4.60p=0.03MonthsofFollow-UpCumulativeSurvivalPETImagingPatternsandMortality

inPatientswithCADandLVDysfunctionViableNonviable#MedicalRevasc.MedicalRevasc.Eitzman836/181/262/240/14DiCarli937/173/263/331/17Lee13710/214/492/402/19Total31323/568/1017/973/50Mortality41%8%7%6%MyocardialViabilityandImpactofRevascularisationinPatientswithCADDiseaseandLVDysfunction:AMeta-Analysis-58.4%ViableNon-viableViableNon-viableREVASCULARISEDMEDICALTHERAPYp<0.0001p<0.001158%Numberofstudies=24N=3,088EF=32%±8%FU25±10MthsDeathRate(%/Yr)Abraham1A,JNuclMed2010;51:567–574AdjustedsurvivalcurvesforPETandstandardarmsinOttawa-FIVEsubstudyContrastMRIvs.FDGSPECTLiuQ,etal.NuclMedComm2009SPECTMRIPerfusionSPECTandFDGPETinDCMandHFSestamibiFDGSestamibiFDGSestamibiFDGQPSQGSMyocardialSPECTandPET/CTImagingGatedperfusionSPECTandFDGPETinHFandLBBBFDGFDGFDGSestamibiSestamibiSestamibiPerfusion/MetabolismmismatchinDCMNegliaD,PharmacologicReports2005;57(suppl):151-155Dipyridamole-inducedmismatchusing13N-NH3/18F-FDGPETinpatientswithIDCAltehoeferC.LBBB:challengingourconceptofmetabolicheartimagingwithfluorine-18-FDGandPET?JNuclMed1998;39:263–265.Kaplan-MeiersurvivalaccordingtothepresenceofMismatchinDCMJNuclCardiol2009;16:769–74BMIandrestmyocardialperfusiondefectpredictscardiacdeathinptswithchronicHFCaiM,etal.IntJCardiovasvImaging2012123I-MIBGANDCHFMetaiodobenzilguanidine(MIBG)isananalogueofthefalseneurotransmitterguanetidine,apotentneuronblockingagentthatactsselectivelyonsympatheticnerves.MIBGandnoradrenalinehaveasimilarmolecularstructureandsharethesameuptakeandstoragemechanismsinthesympatheticnerveendings.MIBGisnotmetabolizedbymonoamineoxidase;thus,localizationofMIBGrelatestothepresenceofsympatheticnervesandtotissuenoradrenalinecontent.MIBGiscurrentlylabelledwith123-Ifordiagnosticpurposesandwith131-Ifortherapy28/11/2006EF=13%EDV=350ml10/07/2007EF=60%EDV=110mlEurJNuclMedmolecularImaging,2009;36:2068AgostiniD.EurJNuclMedMolImaging(2008)35:535–546123-mIBGmyocardialimagingforassessmentofriskforamajorcardiaceventinHFPtsJacobsonAF,etal.JAmCollCardiol.2010May18;55(20):2212-212-YearCardiacDeathandAll-CauseMortalityRatesJacobsonAF,etal.JAmCollCardiol.2010May18;55(20):2212-21CumulativeEventCurvesinRelationtoBNP,LVEF,andH/MJacobsonAF,etal.JAmCollCardiol.2010May18;55(20):2212-21CumulativeEventCurvesinRelationtoBNP,LVEF,andH/MJacobsonAF,etal.JAmCollCardiol.2010May18;55(20):2212-21HSV-ttk报告基因干细胞PET成像18F-FHBG18F-FDGInfluenceofintracoronarystemcelltherapyonLVEF,infarctarea,andFDGmetabolisminPETstudyBeforeTxAfterTxDifferencePValueLVEF,%529607+15%0.0001Infarctarea,%278199-30%0.0001FDG-PET,%43.88.050.511.6+15%0.012ModifiedfromStraueretal.JACCVol.46,No.9,2005RegenerationofHumanInfarctedHeart

MusclebyIntracoronaryAutologousBoneMarrow

CellTransplantationinChronicCAD:TheIACTStudyStraueretal.JACCVol.46,No.9,20050102DilatedCardiomyopathyDuetoDoxorubicin/

AnthracyclineCardiotoxicityRNAisanidealnoninvasivetooltoprovidelongitudinalquantitativeassessmentofLVfunctioninpatientsreceivingdoxo